INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 143 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 0.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $54,000 | -10.0% | 29,790 | -6.7% | 0.00% | – |
| Q1 2019 | $60,000 | +57.9% | 31,943 | 0.0% | 0.00% | – |
| Q4 2018 | $38,000 | +123.5% | 31,943 | +422.2% | 0.00% | – |
| Q3 2018 | $17,000 | +142.9% | 6,117 | +39.3% | 0.00% | – |
| Q2 2017 | $7,000 | -73.1% | 4,391 | -45.5% | 0.00% | – |
| Q1 2017 | $26,000 | +136.4% | 8,057 | 0.0% | 0.00% | – |
| Q4 2016 | $11,000 | -91.7% | 8,057 | -90.6% | 0.00% | -100.0% |
| Q3 2016 | $133,000 | +10.8% | 85,544 | -5.0% | 0.00% | 0.0% |
| Q2 2016 | $120,000 | -82.3% | 90,048 | -30.0% | 0.00% | -66.7% |
| Q1 2016 | $678,000 | -79.2% | 128,672 | -68.9% | 0.00% | -81.2% |
| Q4 2015 | $3,252,000 | +15.7% | 414,310 | +24.5% | 0.02% | +6.7% |
| Q3 2015 | $2,811,000 | +5.5% | 332,718 | +36.8% | 0.02% | +15.4% |
| Q2 2015 | $2,664,000 | +57.1% | 243,246 | +100.5% | 0.01% | +44.4% |
| Q1 2015 | $1,696,000 | +120.0% | 121,309 | +155.8% | 0.01% | +125.0% |
| Q2 2013 | $771,000 | – | 47,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |